Revance Therapeutics (RVNC) Earnings Date, Estimates & Call Transcripts → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free RVNC Stock Alerts $3.08 +0.06 (+1.99%) (As of 11:14 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateAug. 13EstimatedActual EPS (Feb. 28) -$0.62 Beat By $0.17 Consensus EPS (Feb. 28) -$0.79 Read Call TranscriptListen to Call Get Revance Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for RVNC and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRVNC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RVNC Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchWhat President Biden's new law means for investorsWhat's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it.This expert just went public with all the details, including which stocks to jump on immediately. Revance Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.69)($0.56)($0.63)Q2 20242($0.59)($0.56)($0.58)Q3 20242($0.66)($0.49)($0.58)Q4 20242($0.55)($0.43)($0.49)FY 20248($2.49)($2.04)($2.27)Q1 20251($0.49)($0.49)($0.49)Q2 20251($0.26)($0.26)($0.26)Q3 20251($0.26)($0.26)($0.26)Q4 20251($0.20)($0.20)($0.20)FY 20254($1.21)($1.21)($1.21)RVNC Earnings Date and InformationRevance Therapeutics last issued its earnings data on February 28th, 2024. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.17. The firm had revenue of $69.80 million for the quarter, compared to the consensus estimate of $64.02 million. Revance Therapeutics has generated ($3.63) earnings per share over the last year (($3.63) diluted earnings per share). Earnings for Revance Therapeutics are expected to grow in the coming year, from ($1.83) to ($0.74) per share. Revance Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.Read More Revance Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/13/2024Estimated)------- 2/28/2024Q4 2023($0.79)($0.62)+$0.17($0.62)$64.02 million$69.80 million 11/8/2023Q3 2023($1.02)($0.74)+$0.28$0.15$58.49 million$56.78 million8/8/2023Q2 2023($0.72)($0.80)($0.08)($0.80)$58.71 million$58.13 million 5/9/2023Q1 2023($0.75)($0.74)+$0.01($0.74)$46.21 million$49.33 million 2/28/2023Q4 2022($1.04)($1.82)($0.78)($1.82)$45.10 million$49.90 million 11/8/2022Q3 2022($0.85)($1.17)($0.32)($1.17)$28.76 million$29.02 million Get the Latest News and Ratings for RVNC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2022Q2 2022($0.91)($0.88)+$0.03($0.88)$27.64 million$28.37 million5/10/2022Q1 2022($0.91)($0.94)($0.03)($0.94)$23.55 million$25.26 million2/28/2022Q4 2021($0.98)($0.93)+$0.05($0.93)$24.56 million$25.95 million 11/9/2021Q3 2021($1.15)($1.10)+$0.05($1.10)$20.03 million$19.75 million 8/5/2021Q2 2021($1.14)($1.07)+$0.07($1.07)$16.68 million$18.80 million Revance Therapeutics Earnings - Frequently Asked Questions When is Revance Therapeutics's earnings date? Revance Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on RVNC's earnings history. Did Revance Therapeutics beat their earnings estimates last quarter? In the previous quarter, Revance Therapeutics (NASDAQ:RVNC) reported ($0.62) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.79) by $0.17. Learn more on analysts' earnings estimate vs. RVNC's actual earnings. How can I listen to Revance Therapeutics's earnings conference call? The conference call for Revance Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Revance Therapeutics's conference call transcript? The conference call transcript for Revance Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Revance Therapeutics generate each year? Revance Therapeutics (NASDAQ:RVNC) has a recorded annual revenue of $234.04 million. How much profit does Revance Therapeutics generate each year? Revance Therapeutics (NASDAQ:RVNC) has a recorded net income of -$323.99 million. RVNC has generated -$3.63 earnings per share over the last four quarters. What is Revance Therapeutics's EPS forecast for next year? Revance Therapeutics's earnings are expected to grow from ($1.83) per share to ($0.74) per share in the next year. More Earnings Resources from MarketBeat Related Companies: AC Immune Earnings Amarin Earnings Organogenesis Earnings Precigen Earnings Terns Pharmaceuticals Earnings Atea Pharmaceuticals Earnings Verastem Earnings ADC Therapeutics Earnings Korro Bio Earnings Kamada Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?JD’s Earnings Could Mean Chinese Stocks Making a ComebackHome Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-Turn This page (NASDAQ:RVNC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.